Andarine
Also known as: S-4
Status
No approved product. No FDA-approved labeling exists. Not an approved medicine; covered by the FDA's warnings on selective androgen receptor modulators sold in body-building products.
What it is
An early SARM known in reports for temporary vision changes.
What published research measured
One of the earliest selective androgen receptor modulators to reach human study, developed originally for muscle wasting and benign prostatic hyperplasia. Its distinguishing feature in the human literature is an ocular one: andarine binds retinal tissue and produces a reversible yellow tint to vision and difficulty adapting to darkness, a dose-related effect reported consistently enough to have ended its development. Clinical development was discontinued and no efficacy trial supports use for body composition. Like the rest of the class it suppresses the hypothalamic-pituitary-gonadal axis and lowers HDL cholesterol. Prohibited at all times in sport under WADA class S1.2.
Source
Andarine ocular adverse effect literature; discontinued clinical development
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.